KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Intangibles (2017 - 2024)

Aquestive Therapeutics (AQST) has 6 years of Intangibles data on record, last reported at $1.3 million in Q4 2023.

  • For Q4 2023, Intangibles changed N/A year-over-year to $1.3 million; the TTM value through Dec 2023 reached $1.3 million, changed N/A, while the annual FY2023 figure was $1.3 million, N/A changed from the prior year.
  • Intangibles reached $1.3 million in Q4 2023 per AQST's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Intangibles topped out at $7.4 million in Q2 2020 and bottomed at $51000.0 in Q4 2021.
  • Average Intangibles over 5 years is $2.4 million, with a median of $2.9 million recorded in 2019.
  • Peak YoY movement for Intangibles: surged 1773.86% in 2020, then plummeted 98.22% in 2021.
  • A 5-year view of Intangibles shows it stood at $153000.0 in 2019, then soared by 1773.86% to $2.9 million in 2020, then tumbled by 98.22% to $51000.0 in 2021, then surged by 2815.69% to $1.5 million in 2022, then dropped by 14.06% to $1.3 million in 2023.
  • Per Business Quant database, its latest 3 readings for Intangibles were $1.3 million in Q4 2023, $1.5 million in Q3 2022, and $51000.0 in Q4 2021.